6h agoSeeking AlphaBULLISH 76Product/PR
Vaxcyte jumps on phase 3 data for pneumonia vaccine VAX-31
Vaxcyte jumps 32% on phase 3 VAX-31 vaccine data vs Prevnar 20 and Capvaxive. Read more here.
Archived explainer. For the current picture see today's PCVX page.
Why Is VAXCYTE INC (PCVX) Stock Up Today?
By the Top Tier Newswire AI Desk · October 5, 2026 at 11:39 AM ET · reviewed against 20 wire stories
VAXCYTE INC (PCVX) is up +31.55% in the latest session. Our newswire has captured 20 stories on PCVX across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why PCVX stock is up today
Vaxcyte Inc (PCVX) surged 31.55% to $74.30 in the latest session, driven by positive topline data from its pivotal Phase 3 trial for the pneumococcal vaccine candidate VAX-31. The company reported that VAX-31 met all prespecified primary endpoints in adults aged 50 and older and demonstrated noninferiority across 321 immunobridging comparisons against competing vaccines Prevnar 20 and Capvaxive. The results have sparked significant investor interest and optimism about the product’s potential in the market.
What Happened
The stock opened at $91.06, reflecting a 61.2% gap up from the previous close of $56.48. The session saw a high of $93.00 and a low of $73.87 before settling at $74.43. The rally was fueled by the company’s announcement that VAX-31, a 31-valent pneumococcal conjugate vaccine, achieved all primary endpoints in the OPUS-1 trial. The data positioned VAX-31 as a direct competitor to established vaccines from Pfizer and Merck. Analysts from Jefferies and Mizuho highlighted the data as a potential catalyst for the stock, with price targets of $90, $100 and $125 cited in recent commentary.
What The Data Shows
The stock traded at a market cap of $8.4 billion despite being unprofitable, with an earnings per share (EPS) of -7.65 over the trailing twelve months. The session’s volume of 6.2 million shares was 4.6 times the 3-month average, indicating strong participation. The stock has traded between $37.69 and $65.00 over the past 52 weeks, with today’s close surpassing the previous 52-week high of $65.00. The 30-day average sentiment improved from 60/100 to 64/100 in the last week, reflecting growing optimism.
What To Watch
The company has no upcoming earnings report scheduled. Investors should monitor the breadth of analyst coverage and any further developments in regulatory or partnership discussions related to VAX-31.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PCVX by the numbers
Last: $74.30Session: +31.55%7 sessions: +30.43%Coverage: 20 stories / 11 sourcesAI sentiment: 64/100 (bullish)Mkt cap: $8.4B52w: $37.69 to $65.00
The headlines behind the move
7h agoMarketChameleonBULLISH 76Product/PR
PCVX rallies after OPUS-1 Phase 3 data show VAX-31 hit all primary endpoints and cleared 321 immunobridging comparisons
Vaxcyte reported positive topline Phase 3 OPUS-1 results for VAX-31, saying the 31-valent pneumococcal vaccine candidate met all prespecified primary endpoints in adults 50+ and achieved noninferiority across all 321 immunobridging comparisons in adults 18–49. The company said safety was similar to PCV20 and PCV21 and reiterated plans to read out OPUS-2 and OPUS-3 in 1H 2027 ahead of a planned BLA submission in 1H 2028.
7h agoBarron'sBULLISH 73Product/PR
Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
7h agoThe FlyBULLISH 64General
Vaxcyte rises 46.4%
7h agoThe FlyBEARISH 32General
Vaxcyte data hit ‘blue-sky’ case, says Jefferies
7h agoThe FlyBULLISH 67Analyst
Vaxcyte can trade in $90-$100 range on data, says Mizuho
8h agoInvestors.comBULLISH 67Product/PR
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study
9h agoInvestorsHubBULLISH 78Product/PR
Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial
Vaxcyte shares rise 50% after its VAX-31 pneumococcal vaccine candidate met all prespecified primary endpoints in the pivotal OPUS-1 Phase 3 trial.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on PCVX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PCVX move explainers: 2026-10-05